Sacituzumab (powder)

Cat. No.: HY-P99045A: Data Sheet
FAQs
Technical Support

Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.

For research use only. We do not sell to patients.

Sacituzumab (powder) Chemical Structure

CAS No. : 1796566-95-4

Size		Stock
MOQ		Minimum order quantity
1 mg		Get quote
5 mg		Get quote
10 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Sacituzumab (powder):

Sacituzumab

Other Forms of Sacituzumab (powder):

Sacituzumab In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Sacituzumab (0.5 nM, 800 s) possesses non-competitive binding sites and recognized distinct epitopes of TROP-2 on the antigen. Additionally, the binding to cancer cell lines activities of Sacituzumab and hIMB1636 is similar^[1].
Sacituzumab (5 mg/mL, 48 h) binds to a linear epitope within TROP-2, which might not interrupt the assembly of TROP-2 molecules on the cell surface in HEK-293T cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	HEK-293T cells
Concentration:	5 mg/mL
Incubation Time:	48 h
Result:	Bound to the linear epitopes of denatured TROP-2 proteins in HEK 293T cells.

In Vivo

Sacituzumab (50 mg/kg, i.v., every 5 days for four times) exhibits a weak antitumor effect without significant weight loss in MDA-MB-468 xenograft mouse model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MDA-MB-468 xenograft model of 6-week-old female BALB/c nude mice^[1]
Dosage:	50 mg/kg
Administration:	i.v., intervals of 5 days and repeated a total of four times
Result:	Decreased the tumor inhibition rate to 29.1% at 50 mg/kg in MDA-MB-468 xenograft model.

Molecular Weight

145.52 kDa

CAS No.

1796566-95-4

SMILES

[Sacituzumab (powder)]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Zhou DD, et al. Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2[J]. Int J Biol Macromol. 2023 Dec 31;253(Pt 6):127105. [Content Brief]

[2]. Sun M, et al. Structural insights into the cis and trans assembly of human trophoblast cell surface antigen 2[J]. iScience. 2021 Sep 30;24(10):103190. [Content Brief]

[3]. Shih LB, et al. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer[J]. Cancer Res. 1995 Dec 1;55(23 Suppl):5857s-5863s. [Content Brief]

[4]. Bardia A, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021 Sep;32(9):1148-1156. [Content Brief]